- Home
- SKIN vs IKT Comparison
SKIN vs IKT Comparison
Compare SKIN & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKIN
- IKT
- Stock Information
- Founded
- SKIN 1997
- IKT 2008
- Country
- SKIN United States
- IKT United States
- Employees
- SKIN N/A
- IKT N/A
- Industry
- SKIN Package Goods/Cosmetics
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- SKIN Consumer Discretionary
- IKT Health Care
- Exchange
- SKIN Nasdaq
- IKT Nasdaq
- Market Cap
- SKIN 164.1M
- IKT 167.2M
- IPO Year
- SKIN N/A
- IKT 2020
- Fundamental
- Price
- SKIN $1.23
- IKT $2.09
- Analyst Decision
- SKIN Hold
- IKT Buy
- Analyst Count
- SKIN 5
- IKT 2
- Target Price
- SKIN $2.50
- IKT $8.00
- AVG Volume (30 Days)
- SKIN 648.4K
- IKT 129.0K
- Earning Date
- SKIN 03-12-2025
- IKT 05-14-2025
- Dividend Yield
- SKIN N/A
- IKT N/A
- EPS Growth
- SKIN N/A
- IKT N/A
- EPS
- SKIN N/A
- IKT N/A
- Revenue
- SKIN $334,294,000.00
- IKT N/A
- Revenue This Year
- SKIN $1.93
- IKT N/A
- Revenue Next Year
- SKIN $12.41
- IKT N/A
- P/E Ratio
- SKIN N/A
- IKT N/A
- Revenue Growth
- SKIN N/A
- IKT N/A
- 52 Week Low
- SKIN $0.91
- IKT $1.12
- 52 Week High
- SKIN $4.23
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- SKIN 38.14
- IKT 38.54
- Support Level
- SKIN $1.25
- IKT $2.08
- Resistance Level
- SKIN $1.39
- IKT $2.46
- Average True Range (ATR)
- SKIN 0.11
- IKT 0.16
- MACD
- SKIN 0.00
- IKT -0.01
- Stochastic Oscillator
- SKIN 2.86
- IKT 10.91
About SKIN The Beauty Health Company
The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.